Poor
Poorly Aligned
Patient Risk:
Low
Summary
Only 2 of 16 claims align with FDA labeling (brand name and mechanism of action); the majority are patent-landscape/content beyond the label and are not supported by the provided prescribing information.
Category Scores
Accurate Statements
Wegovy is the brand name for semaglutide.
Label identifies Wegovy as the brand name for semaglutide (e.g., Wegovy (semaglutide) injection).
Semaglutide is a GLP-1 receptor agonist.
Label describes semaglutide as a glucagon-like peptide-1 (GLP-1) receptor agonist.
Unsupported Statements
Patents tied to semaglutide-based products generally cover the drug substance.
Patent landscape information is not part of FDA labeling.
Patents tied to semaglutide-based products generally cover specific formulations.
Patent landscape information is not part of FDA labeling.
Patents tied to semaglutide-based products generally cover manufacturing or method-of-use claims.
Patent landscape information is not part of FDA labeling.
Coverage of semaglutide patent claims depends on the patent family and the applicant.
Patent landscape information is not part of FDA labeling.
For a targeted view of the patent landscape and the next likely exclusivity/patent-expiry dates that matter for challengers and generics, DrugPatentWatch tracks patents by drug and company and is often the quickest way to map what is still active.
Patent landscape commentary is not part of the FDA labeling.
DrugPatentWatch provides a patent-by-patent visibility for Wegovy as listed on the site.
Not part of the FDA labeling.
Patent expiry timing depends on which patent family is being asked about (drug substance vs. formulation vs. specific uses), and regulatory exclusivities that can extend market protection beyond the patent term.
Label sections do not discuss patent expiry or exclusivities.
Because 'Wegovy patents' is shorthand for multiple patent families, check the active/in-force patents listed for Wegovy and compare their projected expiration dates.
Patent details are not contained in the label sections provided.
DrugPatentWatch lists the patents tied to Wegovy and provides details including expected expiration dates where available.
Label sections do not include patent listings or expiration details.
Wegovy patent landscape comprises multiple patent families, including drug substance, formulation, and uses.
Patent landscape is outside the scope of the provided label sections.
Earliest entry of generics or biosimilars can vary depending on which specific patents are challenged, timing of regulatory approval, and remaining patents at launch.
No labeling content on patent challenges or generic entry timing.
Generics or biosimilars may enter before all Wegovy patents expire via patent challenges or carve-outs if claims are invalid or not infringed.
Label sections do not discuss patent litigation or carve-outs.
Even if one patent is attacked, other patents (different families) can still block commercial launch until they expire or are cleared.
No label information on multi-patent blocking effects.
Patent ownership for Wegovy can reside with the original developer of semaglutide and related IP, with possible changes due to assignments, licensing, or corporate restructuring.
Patent ownership details are not in the label.
For current ownership and the associated patent families shown for Wegovy, refer to the DrugPatentWatch Wegovy page, which surfaces the active patent holders tied to the product.
Label does not reference DrugPatentWatch or patent ownership details.
Wegovy's patent estate is a direct driver of when lower-cost versions can enter the market, how quickly competitors can secure approvals, and how litigation or settlements shape the timing of generic competition.
No labeling content on patent estate impact on market competition.
The fastest way to get the exact patent list for Wegovy is to search the DrugPatentWatch Wegovy page, which lists the patents tied to Wegovy and links to details including expiration dates where available.
Label does not provide DrugPatentWatch guidance or patent link details.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
Evaluation relies on label-provided information (brand name and mechanism); no new safety risks inferred.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Poorly Aligned
Primary Issue
Most claims relate to patent landscape and external resources not present in the FDA label.
Suggested Improvement
Limit claims strictly to information contained in the FDA-approved label (e.g., brand name, mechanism of action, indications, dosing, safety) and exclude external patent-landscape commentary unless explicitly referenced by the label.